FMR reports 11.7% stake in Lexicon Pharmaceuticals

FMR LLC filed an amended Schedule 13G reporting significant ownership in Lexicon Pharmaceuticals, Inc. common stock.

Rhea-AI Filing Summary

FMR LLC filed an amended Schedule 13G reporting significant ownership in Lexicon Pharmaceuticals, Inc. common stock. FMR LLC is shown as beneficially owning 51,782,044.66 shares, representing 11.7% of the outstanding common stock, with sole dispositive power over that amount.

Abigail P. Johnson is also reported as having sole dispositive power over the same 51,782,044.66 shares, equal to 11.7% of the class. Within this position, Fidelity Growth Company Commingled Pool holds 24,673,450 shares, described as 5.6% of Lexicon’s total outstanding common stock as of June 30, 2026.

Key Figures

Beneficial ownership: 51,782,044.66 shares Percent of class: 11.7% FMR sole voting power: 51,777,773 shares +4 more

7 metrics

Beneficial ownership 51,782,044.66 shares Shares of Lexicon Pharmaceuticals common stock beneficially owned by FMR LLC

Percent of class 11.7% Portion of Lexicon Pharmaceuticals common stock class beneficially owned

FMR sole voting power 51,777,773 shares Shares over which FMR LLC has sole voting power

FMR sole dispositive power 51,782,044.66 shares Shares over which FMR LLC has sole dispositive power

Fidelity Growth Company Commingled Pool 24,673,450 shares Stake in Lexicon common stock, equal to 5.6% as of 06/30/2026

Commingled Pool percent of class 5.6% Percent of total outstanding Lexicon common stock held by Fidelity Growth Company Commingled Pool

As-of date 06/30/2026 Date for the 5.6% ownership figure of Fidelity Growth Company Commingled Pool

Key Terms

beneficially owned, Sole Dispositive Power, Schedule 13G, Investment Company Act of 1940, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 51782044.66"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Dispositive Power financial

"Sole Dispositive Power 51,782,044.66"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"Please see Exhibit 99 for 13d-1(k) (1) agreement."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Investment Company Act of 1940 regulatory

"investment company registered under the Investment Company Act of 1940"

A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

parent holding company financial

"If a parent holding company has filed this schedule"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in LXRX does FMR LLC report on this Schedule 13G/A?

FMR LLC reports beneficial ownership of 51,782,044.66 shares of Lexicon Pharmaceuticals (LXRX) common stock, representing 11.7% of the outstanding class, with sole dispositive power over those shares and no shared voting or dispositive power.

How much of Lexicon Pharmaceuticals (LXRX) stock is attributed to Abigail P. Johnson?

Abigail P. Johnson is reported as having sole dispositive power over 51,782,044.66 shares of LXRX common stock, equal to 11.7% of the class, with no sole or shared voting power disclosed for her individual line item.

What is the position of Fidelity Growth Company Commingled Pool in LXRX?

Fidelity Growth Company Commingled Pool is stated to hold 24,673,450 shares of Lexicon Pharmaceuticals common stock, representing 5.6% of the total outstanding common stock as of June 30, 2026, within the broader FMR LLC aggregated holdings.

Does FMR LLC report sole or shared voting power over LXRX shares?

For FMR LLC, the cover information lists 51,777,773 shares of sole voting power and 0 shared voting power, with sole dispositive power over 51,782,044.66 shares and no shared dispositive power in Lexicon Pharmaceuticals common stock.

Why is this Schedule 13G/A filing for Lexicon Pharmaceuticals (LXRX) significant?

This Schedule 13G/A shows that FMR LLC and related entities collectively hold an 11.7% beneficial ownership stake in LXRX, with one underlying fund alone holding 5.6%, indicating a large institutional position in the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 10:32 AM Accepted by SEC EDGAR 08/06/2026 - 10:31 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

LEXICON PHARMACEUTICALS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

528872302

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 528872302

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 51,777,773.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 51,782,044.66
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

51,782,044.66

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.7 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 528872302

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 51,782,044.66
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

51,782,044.66

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: LEXICON PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 2445 TECHNOLOGY FOREST BLVD.,SUITE 1100,THE WOODLANDS,TX,USA,77381
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 528872302
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 51782044.66
(b)	Percent of class: 11.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 51782044.66
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of LEXICON PHARMACEUTICALS INC. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of LEXICON PHARMACEUTICALS INC, amounted to 24673450.00 shares or 5.6% of the total outstanding COMMON STOCK at 06/30/2026.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	08/05/2026

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	08/05/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.